FAPI Clinical Development Updates
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
ICPO Theranostics FAP Summit (virtual)
November 5, 2022 […]
Focus on FAPI Newsletter – October 2022
A WORD FROM OUR CHIEF SCIENTIFIC OFFICER
We are excited to launch our FAPI newsletter […]
SOFIE submits IND for [18F]-FAPI-74 in Phase 2 study of Gastrointestinal Cancers
Dulles, VA – October 31, 2022 – SOFIE Biosciences (SOFIE), an established US manufacturer and developer […]
First Patient Imaged in SOFIE’s FAPI Phase II Trial
SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged […]
Monitoring Therapeutic Response to Anti-Fibroblast Activation Protein (FAP) CAR T Cells using [18F]AlF-FAPI-74
Iris K Lee, Estela Noguera-Ortega, Zebin Xiao, Leslie Todd, John Scholler, Decheng Song, Maria Liousia, […]
Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types
Ammar Alfteimi, Ulf Lützen, Alexander Helm, Michael Jüptner, Marlies Marx, Yi Zhao, Maaz Zuhayra
Abstract
Current Status of Clinical Trials on FAP Targeted Radiopharmaceuticals
Presented by: Sherly Mosessian, PhD, SOFIE Chief Scientific Officer
Gordon Research Conference-Radionuclide Theranostics for the Management […]
Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities
Wolfgang P Fendler, Kim M Pabst, Lukas Kessler, Pedro Fragoso Costa, Justin Ferdinandus, Manuel Weber, […]
FAPI featured in accolades at annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting
Congratulations to investigators at Hannover School of Medicine and Heidelberg University Hospital for receiving the […]